ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.
Also called NCT07687056
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,500 participants
- Registry
-
NCT07687056
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07687056. Randomized; single masking; primary purpose treatment. Start 2026-08-11 (actual); primary completion 2030-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
- Acronym
- ACT-REACT
- Condition
- Stroke, Acute Ischemic
- Condition
- Endovascular Thrombectomy
- Condition
- Acute Ischemic Stroke AIS
- Intervention (Biological)
- Tenecteplase or Alteplase- depending upon availability at each treating centre
- Intervention (Other)
- Control
- Lead sponsor
- University of Calgary
- Collaborator
- The George Institute for Global Health, Australia
Record details
- Record id
cardio:ct-nct07687056- Content hash
b172ce90a020c5c3616f7035b7c5b8c49dfafd88dc969a811ae1053c738fe968